Improved Overall Survival in Melanoma with Combined Dabrafenib and TrametinibCaroline Robert, Dirk Schadendorf, Andrzej Maćkiewicz et al.|New England Journal of Medicine|2014Cited by 2.7k
Combi-V: a Randomised, Open-Label, Phase III Study Comparing the Combination of Dabrafenib (D) and Trametinib (T) with Vemurafenib (V) As First-Line Therapy in Patients (Pts) with Unresectable or Metastatic Braf V600E/K Mutation-Positive Cutaneous MelanomaCaroline Robert, Dirk Schadendorf, Bogusława Karaszewska et al.|Annals of Oncology|2014Cited by 7